시장보고서
상품코드
1623465

세계의 당뇨병용 펜 시장 규모 : 지역별, 범위 및 예측

Global Diabetes Pen Market Size By Product Type (Disposable, Reusable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), By Patient Population (Type 1 Diabetes, Type 2 Diabetes), By Geographic Scope And Forecast

발행일: | 리서치사: Verified Market Research | 페이지 정보: 영문 202 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

당뇨병용 펜 시장 규모와 예측

당뇨병용 펜 시장 규모는 2024년에 165억 2,000만 달러로 평가되며, 2031년에는 293억 5,000만 달러에 달할 것으로 예측되며, 2024-2031년의 CAGR은 7.45%로 성장합니다. 당뇨병 펜은 인슐린 및 기타 당뇨병 치료제를 정확하고 편리하게 투여할 수 있는 의료기기입니다. 일반적으로 인슐린 또는 약물 카트리지와 일회용 주사 바늘이 달린 펜 모양의 주사기로 구성됩니다. 사용자는 펜으로 원하는 복용량을 선택하고 피하로 약물을 투여합니다. 당뇨병 환자들은 사용 편의성, 정확한 복용량 및 휴대 성으로 인해 매일 인슐린 치료에 당뇨병 펜을 사용하는 것이 일반적입니다. 당뇨병 펜은 표준 주사기보다 주사 과정을 더 쉽고 번거롭지 않게 만들어 당뇨병 치료를 단순화하는 것을 목표로합니다.

당뇨병 펜은 기능성과 사용 편의성 향상에 초점을 맞춘 지속적인 개발로 인해 유망한 분야로 떠오르고 있습니다. 디지털 기술이 탑재된 스마트 펜은 인슐린 투여량을 측정하고 사용자와 의료 서비스 프로바이더 모두에게 실시간 데이터를 제공하여 더 나은 당뇨병 치료를 가능하게 합니다.

침을 사용하지 않는 주사 방법과 인슐린 제제의 발전은 환자의 편의성과 순응도를 향상시킬 수 있는 잠재력을 가지고 있습니다. 맞춤형 기능을 갖춘 펜의 개발과 디지털 건강 시스템과의 연결성 향상은 당뇨병 치료를 더욱 개인화하고 효율화함으로써 당뇨병 치료를 더욱 변화시킬 수 있는 잠재력을 가지고 있습니다. 당뇨병이 점점 더 흔해짐에 따라 이러한 개발은 당뇨병을 더 잘 관리하는 데 중요한 역할을 할 것으로 보입니다.

세계 당뇨병용 펜 시장 역학

세계 당뇨병 펜 시장을 형성하는 주요 시장 역학

주요 시장 성장 촉진요인

당뇨병 유병률 증가 :

당뇨병 펜 시장은 당뇨병 유병률 증가에 힘입어 성장하고 있습니다. 국제당뇨병연맹(IDF)은 2021년에는 약 5억 3,700만 명의 성인(20-79세)이 당뇨병을 앓고 있을 것으로 추정하고 있습니다. 이 수치는 2030년에는 6억 4,300만 명, 2045년에는 7억 8,300만 명으로 증가할 것으로 예상됩니다.

자가 관리 장비에 대한 수요 증가 :

Journal of Diabetes Science and Technology 저널에 게재된 조사에 따르면 환자의 71%가 인슐린 투여를 위해 바이알이나 주사기 대신 인슐린 펜을 선택했으며, 인슐린 펜이 삶의 질과 치료 만족도를 향상시킨다고 주장했습니다. 치료 만족도 향상을 주장하고 있습니다.

의료비 지출 증가 :

특히 개발도상국의 의료비 지출 증가는 당뇨병 펜 시장을 주도하고 있습니다. 세계보건기구(WHO)의 추산에 따르면 세계 당뇨병 지출은 2019년 7,600억 달러, 2030년 8,250억 달러, 2045년 8,450억 달러에 달할 것으로 예상하고 있습니다.

주요 과제

바늘 공포증:

당뇨병 치료 펜은 편리함에도 불구하고 주사바늘을 사용해야 하므로 많은 환자에게 큰 문제가 될 수 있습니다. 주사와 관련된 두려움과 불편 함은 인슐린 투여를 준수하지 않아 혈당 조절을 손상시킬 수 있습니다. 이 문제를 해결하기 위해 바늘없는 주사기 및 당뇨병 펜을 사용할 때 환자의 편안함과 신뢰를 향상시키기 위한 전술에 대한 지속적인 연구가 진행되고 있습니다.

높은 비용:

당뇨병 펜은 고가이며, 특히 디지털 기능을 갖춘 최신 펜은 고가입니다. 특히 저소득층 환자에게는 높은 초기 구매 가격과 일회용 부품의 지속적인 필요성이 장벽이 될 수 있습니다. 이러한 비용 부담은 중요한 당뇨병 치료 툴에 대한 접근성을 제한하고 건강 격차의 원인이 될 수 있습니다. 더 많은 사람들이 당뇨병 펜을 사용할 수 있도록 하려면 제조업체는 제조 비용을 낮추거나 더 경제적인 대안을 찾아야 합니다.

사용자 교육 및 훈련 :

인슐린 펜을 올바르게 사용하기 위해서는 충분한 교육과 훈련이 필요합니다. 인슐린 펜의 올바른 사용법을 충분히 이해하지 못하면 복용량이나 투여 방법을 잘못 사용할 수 있습니다. 인슐린 펜의 효과적이고 올바른 사용을 보장하기 위해서는 종합적인 교육 프로그램과 환자 및 의료진에 대한 지속적인 지원이 필요합니다.

변동하는 인슐린 흡수:

인슐린의 흡수는 주사 부위, 피부 유형, 주사 기술에 따라 달라질 수 있습니다. 이러한 변동성은 혈당 조절과 당뇨병 치료 전반에 영향을 미칠 수 있습니다. 이 문제를 극복하기 위해서는 인슐린 제제의 개선과 인슐린을 보다 일정하게 전달할 수 있는 장비 설계에 대한 연구가 필요합니다.

주요 동향

무침주사 혁신 :

침을 사용하지 않는 주사 기기의 발전이 당뇨병 펜 시장에서 인기를 끌고 있습니다. 이 장비는 기존 주사바늘을 사용하는 펜에 수반되는 불편함과 심리적 장애물을 줄이는 것을 목표로 하고 있습니다. 제트 주사 및 마이크로니들 기술과 같은 기술을 사용하는 무침 펜은 인슐린 투여에 있으며, 편안하고 방해가 되지 않는 옵션을 제공하여 바늘을 두려워하는 환자나 보다 편리한 솔루션을 원하는 환자들에게 매력적인 선택지가 되고 있습니다.

디지털 헬스 플랫폼과의 통합:

당뇨병 펜은 디지털 건강 플랫폼 및 전자건강기록(EHR)과의 연동이 점점 더 많이 이루어지고 있습니다. EHR과의 통합은 환자 데이터 수집을 더욱 철저하게 하고, 의료 서비스 프로바이더와의 연락을 개선하며, 전체 당뇨병 관리를 개선하기 위해 의료 서비스 프로바이더와의 연락을 개선할 수 있도록 도와줍니다. 개선됩니다.

개별화된 인슐린 투여:

개개인의 필요에 맞는 인슐린 투여 장비에 대한 중요성이 점점 더 강조되고 있습니다. 최신 당뇨병 환자 펜은 다양한 유형의 인슐린과 용량을 사용할 수 있도록 설계되어 환자 개개인의 필요에 따라 맞춤 치료를 할 수 있습니다. 이러한 추세는 개인별 건강 프로파일에 맞게 치료법을 조정하여 치료 효과와 환자 만족도를 높이는 맞춤형 의료에 대한 큰 추진력과 일치합니다.

사용자 경험의 중요성:

당뇨병 펜은 사용자 경험 향상에 중점을 두고 있습니다. 제조업체들은 인체공학적 디자인, 직관적인 인터페이스, 조정 가능한 기능 등에 투자하여 사용 편의성을 향상시키기 위해 노력하고 있습니다. 이러한 접근 방식은 인슐린 투여를 가능한 한 간단하고 편안하게 만들어 일상적인 사용에 대한 장벽을 낮추고 환자의 치료 요법 순응도를 향상시키기 위한 것입니다.

목차

제1장 서론

  • 시장 정의
  • 시장 세분화
  • 조사 방법

제2장 개요

  • 주요 조사 결과
  • 시장 개요
  • 시장 하이라이트

제3장 시장 개요

  • 시장 규모와 성장 가능성
  • 시장 동향
  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 시장 기회
  • Porter's Five Forces 분석

제4장 당뇨병용 펜 시장 : 인슐린 유형별

  • 속효형 인슐린 펜
  • 기초 인슐린 펜

제5장 당뇨병용 펜 시장 : 유통 채널별

  • 병원 약국
  • 소매 약국
  • 온라인 소매업체

제6장 당뇨병용 펜 시장 : 환자층별

  • 1형 당뇨병 환자
  • 2형 당뇨병 환자

제7장 지역별 분석

  • 북미
  • 미국
  • 캐나다
  • 멕시코
  • 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 아시아태평양
  • 중국
  • 일본
  • 인도
  • 호주
  • 라틴아메리카
  • 브라질
  • 아르헨티나
  • 칠레
  • 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트

제8장 시장 역학

  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 시장 기회
  • 시장에 대한 COVID-19의 영향

제9장 경쟁 구도

  • 주요 기업
  • 시장 점유율 분석

제10장 기업 개요

  • Novo Nordisk(Denmark)
  • Eli Lilly and Company(US)
  • Sanofi(France)
  • BD(Becton, Dickinson and Company)(US)
  • Ypsomed Group(Switzerland)
  • Merck & Co., Inc.(US)
  • Boehringer Ingelheim(Germany)
  • AstraZeneca plc(UK)
  • Wockhardt Limited(India)
  • Insulet Corporation(US)

제11장 시장 전망과 기회

  • 신규 기술
  • 향후 시장 동향
  • 투자 기회

제12장 부록

  • 약어 리스트
  • 전시와 참고 문헌
KSA 25.01.17

Diabetes Pen Market Size And Forecast

Diabetes Pen Market size was valued at USD 16.52 Billion in 2024 and is projected to reach USD 29.35 Billion by 2031 , growing at a CAGR of 7.45% from 2024 to 2031. A diabetes pen is a medical device that allows you to precisely and conveniently deliver insulin or other diabetes treatments. It usually consists of a pen-like injector with a cartridge of insulin or medicine and a disposable needle. The user selects the desired dose on the pen and administers the medication subcutaneously. Individuals with diabetes commonly utilize diabetes pens for daily insulin therapy due to their ease of use, accurate dose, and portability. They are intended to simplify diabetes care by making the injection process more user-friendly and less laborious than with standard syringes.

Diabetes pens look promising, with continual developments focused on enhancing functionality and user experience. Smart pens equipped with digital technology measure insulin doses and offer real-time data to both users and healthcare providers, allowing for better diabetes treatment.

Research into needle-free injection methods and insulin formulation advancements may increase patient comfort and adherence. The development of pens with customized features and improved connectivity to digital health systems has the potential to further change diabetes care by making it more personalized and efficient. As diabetes becomes increasingly common, these developments will play an important role in better managing the disease.

Global Diabetes Pen Market Dynamics

The key market dynamics that are shaping the global diabetes pen market include:

Key Market Drivers:

Increasing Prevalence of Diabetes:

The diabetes pen market is driven by the increasing prevalence of diabetes. The International Diabetes Federation (IDF) estimates that roughly 537 million adults (20-79 years old) will have diabetes in 2021. This figure is expected to climb to 643 million by 2030, and 783 million by 2045.

Rising Demand for Self-Administration Devices:

Diabetes pens are becoming increasingly popular because of their convenient and user-friendly nature. Research published in the Journal of Diabetes Science and Technology discovered that 71% of patients chose insulin pens to vials and syringes for insulin delivery, claiming increased quality of life and treatment satisfaction.

Increasing Healthcare Expenditure:

Rising healthcare spending, especially in developing nations, is driving the diabetes pen market. The World Health Organization (WHO) estimates that global diabetes spending hit $760 billion in 2019 and is expected to reach $825 billion by 2030 and $845 billion by 2045.

Key Challenges:

Needle Phobia:

Diabetes pens, despite their convenience, need the usage of needles, which can be a major issue for many patients. Fear or discomfort associated with injections may lead to noncompliance with insulin administration, compromising blood sugar management. To address this issue, continuous research is being conducted into needle-free injection devices and tactics for improving patient comfort and trust when using diabetic pens.

High Costs:

Diabetes pens are expensive, particularly modern kinds with digital features. The high initial purchase price and continued requirement for disposable components might be a barrier for patients, especially in low-income areas. This cost burden may restrict access to critical diabetes care tools, contributing to health inequities. To make diabetic pens more accessible to a larger audience, manufacturers must find ways to cut production costs or produce more economical alternatives.

User Training and Education:

Adequate training and education are required for the proper use of insulin pens. Inadequate understanding of how to use the device correctly can result in incorrect dose or delivery. Comprehensive training programs and continuing support for patients and healthcare providers are required to guarantee the effective and correct use of diabetes pens.

Variable Insulin Absorption:

Insulin absorption varies depending on the injection site, skin type, and injection technique. This fluctuation can have an impact on blood glucose control and diabetes treatment in general. To overcome this issue, research into refining insulin formulations and designing devices for more constant insulin delivery is required.

Key Trends:

Needle-Free Innovations:

Advancements in needle-free injection devices are gaining popularity in the diabetes pen market. The devices are intended to decrease the discomfort and psychological hurdles associated with traditional needle-based pens. Needle-free pens, which use technologies such as jet injection or microneedle technology, provide a more comfortable and less intrusive option for insulin delivery, making them appealing to patients who are afraid of needles or who want a more convenient solution.

Integration with Digital Health Platforms:

Diabetes pens are becoming more linked with digital health platforms and electronic health records (EHRs). This development allows for more smooth data transmission between devices and healthcare systems, which improves diabetes monitoring and control. Integration with EHRs enables more thorough gathering of patient data, improved contact with healthcare providers, and better overall diabetes management.

Personalized Insulin Delivery:

There is an increasing emphasis on insulin administration devices that are tailored to individual patient needs. Modern diabetic pens are intended to accommodate a variety of insulin kinds and dosages, allowing for personalized therapy depending on individual patient needs. This tendency is consistent with the larger push toward personalized medicine, in which therapies are tailored to individual health profiles, increasing efficacy and patient satisfaction.

Focus on User Experience:

Diabetes pens place a great emphasis on improving the user experience. Manufacturers are investing in ergonomic designs, intuitive interfaces, and adjustable features to improve usability. This approach tries to make insulin administration as simple and comfortable as feasible, lowering barriers to regular use and improving patient adherence to treatment regimens.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Diabetes Pen Market Regional Analysis

Here is a more detailed regional analysis of the global diabetes pen market:

North America:

North America holds the lead in the diabetic pen market due to several relevant reasons. The high prevalence of diabetes in the region, along with a well-developed healthcare infrastructure and a strong presence of large pharmaceutical corporations, has led to the widespread use of insulin pens. The complex healthcare system in North America promotes the incorporation of advanced diabetes management systems, resulting in a large market for these goods. The concentration of prominent pharmaceutical companies has fueled innovation in diabetes pen technology, resulting in a wide selection of devices adapted to different patient needs.

The rising prevalence of diabetes in North America is a major driver of market expansion. According to the CDC, around 37.3 million Americans had diabetes in 2021, with a projected increase to 60.6 million by 2060. Diabetes has a significant economic burden, with direct medical expenses estimated at USD 374 Billion per year. This highlights the need for effective treatment tools such as insulin pens. Technological improvements drive market expansion. This expansion is being driven by greater adoption of connected devices and a demand for more personalized diabetes care options.

Asia Pacific:

The Asia Pacific diabetes pen market is rapidly expanding, owing to the high prevalence of diabetes in densely populated countries such as China and India. The rising prevalence of diabetes, combined with increased awareness and access to healthcare, is driving growing demand for insulin pens. Insulin pens are gaining popularity as a cost-effective and user-friendly alternative to standard injectable procedures. This shift to insulin pens is helped by the region's increasing healthcare infrastructure, which encourages the widespread use of modern diabetes control tools.

The high prevalence of diabetes in Asia Pacific is a key driver of market growth. The International Diabetes Federation (IDF) forecasts that 206 million adults in the Western Pacific region will have diabetes in 2021, with this total expected to climb to 260 million by 2045. China alone had 140.9 million cases in 2021, with a projected increase to 174.4 million by 2045. Diabetes's economic impact in the region, which is expected to be USD 241 Billion in 2021, highlights the need for efficient and cost-effective management solutions. The growing diabetic population, as well as the increased adoption rates of insulin pens, show the region's growing demand for effective diabetes care options.

Global Diabetes Pen Market: Segmentation Analysis

The Global Diabetes Pen Market is Segmented on the basis of Product Type, Distribution Channel, Patient Population, And Geography.

Diabetes Pen Market, By Product Type

  • Disposable
  • Reusable

Based on Product Type, the market is fragmented into Disposable and Reusable. The disposable segment of the diabetes pen market dominates due to its simplicity and ease of usage. Many patients prefer disposable pens due to they are simple to use and eliminate the need for cleaning and refilling. The reusable category is rapidly expanding. Reusable pens save money over time and are becoming increasingly popular as patients look for more environmentally friendly and cost-effective solutions. The increased preference for reusable pens indicates a trend toward long-term value and environmental conscience, which is fueling their rapid market growth.

Diabetes Pen Market, By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Retailers

Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Retailers. Retail pharmacies are the dominant segment in the diabetic pen market due to their widespread accessibility and established presence, which allows patients to acquire diabetes pens on demand. Online merchants are the fastest-growing segment, driven by the expanding popularity of e-commerce and the convenience of online buying. Online platforms provide greater product selections, home delivery, and often cheaper pricing, attracting an increasing number of customers looking for a more convenient and flexible purchase experience.

Diabetes Pen Market, By Patient Population

  • Type 1 Diabetes
  • Type 2 Diabetes

Based on Patient Population, the market is segmented into Type 1 Diabetes and Type 2 Diabetes. The Type 2 Diabetes segment is dominating the diabetes pen market due to its higher prevalence than Type 1 diabetes. As Type 2 diabetes becomes more prevalent, there is an increased demand for diabetes care solutions among these individuals. Type 1 Diabetes is the fastest-growing group, owing to increased awareness and breakthroughs in treatment technologies. The rising emphasis on personalized insulin delivery systems, as well as diabetes care advancements, are fueling the Type 1 diabetes segment's rapid growth.

  • Diabetes Pen Market
  • , By Geography
  • North America
  • Europe
  • Asia Pacific
  • Rest of the World
  • On the basis of Geography, the Global
  • Diabetes Pen Market
  • is classified into North America, Europe, Asia Pacific, and the Rest of the World. North America dominates the diabetic pen market, owing to its high prevalence of diabetes, modern healthcare infrastructure, and powerful pharmaceutical businesses. The Asia Pacific area is growing fastest, owing to rising diabetes incidence, more awareness, and improved healthcare access in nations such as China and India. This region's significant population and rapid economic development are driving up demand for diabetes pens, making it a viable market in the future.

Key Players

  • The "Global
  • Diabetes Pen Market
  • " study report will provide valuable insight with an emphasis on the global market. The major players in the market are
  • Novo Nordisk, Eli Lilly and Company, Sanofi, BD (Becton, Dickinson and Company), Ypsomed Group, Merck & Co., Inc., Boehringer Ingelheim, AstraZeneca plc, Wockhardt Limited, and Insulet Corporation.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

  • Diabetes Pen Market
  • Recent Developments
  • In September 2023, Eli Lilly announced a 70% price reduction for its most popular insulins and expanded its Insulin Value Program. The program now limits patients' out-of-pocket expenses to $35 per month. To help patients even more, Eli Lilly implemented a $35 monthly cap on insulin-related medications. This approach attempts to keep patients from experiencing financial hardship as a result of high insulin prices.
  • In October 2022, Novo Nordisk announced the completion of the Forma Therapeutics acquisition.
  • In December 2022, Sanofi and Innate Pharma will expand their relationship in oncology with natural killer cell therapies.

TABLE OF CONTENTS

1. Introduction

  • Market Definition
  • Market Segmentation
  • Research Methodology

2. Executive Summary

  • Key Findings
  • Market Overview
  • Market Highlights

3. Market Overview

  • Market Size and Growth Potential
  • Market Trends
  • Market Drivers
  • Market Restraints
  • Market Opportunities
  • Porter's Five Forces Analysis

4. Diabetes Pen Market, By Insulin Type

  • Rapid-Acting Insulin Pens
  • Basal Insulin Pens

5. Diabetes Pen Market, By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Retailers

6. Diabetes Pen Market, By Patient Population

  • Type 1 Diabetes Patients
  • Type 2 Diabetes Patients

7. Regional Analysis

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • Latin America
  • Brazil
  • Argentina
  • Chile
  • Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE

8. Market Dynamics

  • Market Drivers
  • Market Restraints
  • Market Opportunities
  • Impact of COVID-19 on the Market

9. Competitive Landscape

  • Key Players
  • Market Share Analysis

10. Company Profiles

  • Novo Nordisk (Denmark)
  • Eli Lilly and Company (US)
  • Sanofi (France)
  • BD (Becton, Dickinson and Company) (US)
  • Ypsomed Group (Switzerland)
  • Merck & Co., Inc. (US)
  • Boehringer Ingelheim (Germany)
  • AstraZeneca plc (UK)
  • Wockhardt Limited (India)
  • Insulet Corporation (US)

11. Market Outlook and Opportunities

  • Emerging Technologies
  • Future Market Trends
  • Investment Opportunities

12. Appendix

  • List of Abbreviations
  • Sources and References
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제